Humana Inc. Stock
€348.00
Your prediction
Humana Inc. Stock
Humana Inc. (Symbol: HUM) is a leading healthcare and wellness company headquartered in Louisville, Kentucky, specializing in offering a diversified range of health insurance, wellness programs, and managed care plans to individual, group, government, and military customers. With a strong commitment to providing personalized, affordable, and high-quality healthcare solutions, Humana emphasizes on simplifying access and meeting the evolving needs of its vast clientele through leveraging data analytics, technology, and innovation. As a publicly traded entity, Humana’s stock is listed on the New York Stock Exchange, and it forms part of the esteemed S&P 500 index, reflecting its significant impact and presence within the highly competitive healthcare sector.
Pros and Cons of Humana Inc. in the next few years
Pros
Cons
Performance of Humana Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Humana Inc. | -4.440% | 4.819% | 26.087% | 68.523% | 58.470% | -15.060% | -8.589% |
| Centene Corp. | 0.470% | 3.049% | 15.810% | 110.140% | 72.032% | -3.598% | -4.832% |
| Cigna Corp. | -0.280% | 1.855% | 8.134% | -7.405% | 7.719% | -1.559% | 25.859% |
| UnitedHealth Group Inc. | -1.240% | -2.131% | 13.046% | 39.776% | 31.121% | -16.023% | 6.462% |
Comments
News
3 Stocks Doing the Heavy Lifting in Healthcare’s Rebound
Key Points
- Interested in Eli Lilly and Company? Here are five stocks we like better.
- Eli Lilly, Humana, and DexCom have driven a broad healthcare sector recovery, with the sector gaining 5.4%
AdaptHealth Conference: Kaiser Deal Drives Growth, Labor Costs Dent EBITDA
AdaptHealth (NASDAQ:AHCO) told investors at a Bank of America event that first-quarter results reflected broad organic growth across its business
Profound Medical Q1 Earnings Call Highlights
Profound Medical (NASDAQ:PROF) reported sharply higher first-quarter revenue and reiterated its view that adoption of its TULSA prostate treatment platform is moving toward broader commercial use